Debio 9902 - ZT-1 - Debiopharm

Home » Media » Press Releases

Debio 9902 - ZT-1

Date	Article Title
21 Oct 2008	Clinical Update – Debio 9902 SR (ZT-1) for Alzheimer Patients - Debiopharm Starts Tablet Formulation Bridging Study under IND
04 Mar 2008	Clinical Update – Debio 9902 SR in Alzheimer’s disease
10 Jun 2007	Clinical update - Debio 9902 (ZT-1) for Alzheimer´s disease
27 Feb 2007	Clinical update-Debio-9902 SR (ZT-1) implant for Alzheimer´s disease-First patients enroll in Phase II "BRAINz" study
25 Apr 2006	Debiopharm presents phase I monthly implant and phase II daily oral results of ZT-1 for Alzheimer´s disease
13 May 2004	Debiopharm exercises its Option and signs a License Agreement with the Shanghai Institute of Materia Medica for the Development and Commercialisation of ZT-1
06 Nov 2003	Debiopharm presents results of a first monthly injectable sustained-release fomulation of ZT-1 for Alzheimer´s Disease
20 Oct 2003	Debiopharm SA starts a Phase II trial for a once daily oral formulation of ZT-1 to treat Alzheimer´s
21 Jun 2002	H3 Pharma announces promising developments for the treatment of Alzheimer´s disease

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group